Gene Therapy Boosts Parkinsons Disease Drug Benefits
Immunohistochemistry of -synuclein showing positive staining of substantia nigra Lewy bodies in Parkinsons disease.Credit: Wikipedia
In late-stage Parkinsons disease, the relentless loss of dopamine-releasing neurons reduces the therapeutic effect of the symptoms of the drug levodopa. However, new preclinical studies in northwestern medicine show that gene therapy targeting the substantia nigra, the small brain region where these neurons reside, greatly enhances the benefits of levodopa.
NS Gene therapy Recovered Neuron Converts levodopa to dopamine in the substantia nigra. In essence, this allowed levodopa to recreate the environment found in a healthy brain, eliminating the abnormal brain activity that causes difficulty in movement.
In the same study, scientists also explain why dopamine-releasing neurons are lost in the disease. The authors use advanced genetic tools to trigger a series of events that faithfully reproduce what damage to the power plant in dopamine-releasing neurons occurs in the brain circuits of Parkinsons disease. Indicates that.
Mouse survey results released on November 3 NatureMay help identify humans in the early stages of Parkinsons disease and develop and delay treatments Disease progression Treat late-stage illness.
Important new discoveries:
Other northwestern writers are Patricia Gonzalez Rodriguez, Enrico Zampes, Kristen Stout, Jamie Gusman, Ben Yang, Tatiana Tatchat, Emma Irisik, and Paul Schumacker.
Genetic Predispositions Reducing Differentiation Yield Of Mda Neurons
In vitro neural development was impaired in neural lines derived from patients carrying LRRK2, PRKN, SNCA, and sporadic mutations,,,. In four independent studies, the differentiation potential of neural progenitor cells derived from patients was significantly reduced, demonstrated by low yields of neurons in comparison with control lines,,,,. A recent review presented the idea that PD is attributed to significant neurodevelopmental defects, which may increase the susceptibility for disease onset. If confirmed, identifying genetic predispositions that contribute to early developmental defects in iPSC-PD may assist the development of novel PD therapies. However, these phenotypes may appear in conflict with other studies,, capable of generating functional neurons from cell lines with similar mutations. The differences could be due to varying protocols, which may be more or less stressful for the cells.
What If I Carry The Gene
There are ongoing clinical trials testing therapies to treat people who have Parkinson’s and carry certain gene mutations. Proving that it can be important to know which gene mutation you carry. Consult with your doctor when considering a genetic test to determine if you are eligible to participate in gene-based clinical trials.
The Parkinsons Foundation study, PD GENEration: Mapping the Future of Parkinsons Disease, is the first national study to offer genetic testing and counseling at no cost for those with a confirmed Parkinsons diagnosis. Learn more and enroll at Parkinson.org/PDGENEration.
*Please note that not all content is available in both languages. If you are interested in receiving Spanish communications, we recommend selecting both” to stay best informed on the Foundation’s work and the latest in PD news.
Read Also: What Are The Four Cardinal Signs Of Parkinson’s Disease
What Should You Know About At
Genetic tests are not a substitute for a Parkinson’s diagnosis. Most at-home genetic tests do not provide genetic counseling services to help interpret the results. Always consult with a genetic counselor and your doctor before and after taking a genetic test. Most at-home genetic tests check for a limited number of gene mutations associated with Parkinson’s. This can be misleading since these tests may not be comprehensive.
Since scientists are still discovering more PD-associated genes, it is important to consult your doctor about comprehensive genetic testing options, like the PD GENEration study, which provides a free comprehensive genetic test identifying all possible variants in the two most common PD genes.
Even if you or a loved-one test positive for a Parkinson’s gene, it does not mean either of you will develop it. Having a genetic mutation only means that you may be at increased risk to develop PD. Environmental factors and lifestyle choices will help determine whether someone will get Parkinson’s.
Who Should Consider A Genetic Test For Parkinsons
There are two groups of people who might consider getting genetic testing and we will discuss each group separately.
Genetic testing for PD is a common request and a number of commercial labs perform panels of genetic testing for PD. You may ask: How can I test myself for Parksinons? Whether youre considering getting a genetic test through your doctor, or performing one at home, its important to note that at-home test dont map the entire gene for mutations. Genetic testing through your doctor will test for GBA, PARK7, SNCA, LRRK2, parkin and PINK1.
Both groups are faced with two questions: Should I get genetic testing? And if so, what should I do with the results? Before we address these two questions, we need to learn more about the complexity of genetic testing in PD.
Don’t Miss: What Does Parkinson’s Feel Like
The Promise Of Gene Therapy
Gene therapy is a category of treatments that involve introducing DNA into cells in an effort to alter which proteins are created and thereby improve symptoms or even cure disease.
For decades, researchers have been trying to perfect gene therapy treatments for a variety of conditions, but progress has been slow. There have been successes for certain rare genetic disorders which are characterized by a single, well-described mutation in a particular gene. In this situation, a healthy gene is introduced into the cells of these patients. The cells machinery then uses the healthy gene to create a healthy protein, which can effectively cure the patient. Diseases that have been helped in this manner include severe combined immune deficiency, adenosine deaminase deficiency, and hemophilia.
It is much more difficult to attempt gene therapy for diseases that involve more complicated DNA changes. Nevertheless, there has been much effort and some success in using gene therapy techniques to treat cancer, for example, a very complex disease which typically involves many genetic changes.
How gene therapy works
Thanks For Signing Up
We are proud to have you as a part of our community. To ensure you receive the latest Parkinsons news, research updates and more, please check your email for a message from us. If you do not see our email, it may be in your spam folder. Just mark as not spam and you should receive our emails as expected.
Read Also: Are Adjustable Beds Good For Parkinson’s Patients
Genetics Testing In Parkinson’s Disease
Genetic testing in Parkinson’s disease can play an important role in diagnosing the illness. Scientists hope that the knowledge provided by genetics will ultimately help slow or stop its progression.
Genes are carried in our DNA, units of inheritance that determine the traits that are passed down from parent to child. We inherit about 3 billion pairs of genes from our mothers and fathers. They determine the color of our eyes, how tall we may be and, in some instances, the risk we have in developing certain diseases.
As a physician, I know the role that genetics plays in determining our health. The degree of influence that our genes have varies depending on the disease, but both environmental factors and genetics contribute to the development of illness to some extent.
Faqs: Genetics & Parkinsons
If I have Parkinson’s disease will my child get it too? Will I inherit Parkinson’s if my parent or grandparent has it?
Most people with Parkinson’s have no known genetic link. Their children will likely never develop Parkinson’s. There are some known genetic variations that increase the risk of getting Parkinson’s, but most people with these variations do not get Parkinson’s. Like many other diseases, Parkinson’s is a result of a complex interaction between genes and environmental factors.
In a small number of people , Parkinson’s is inherited and can affect multiple family members. Their children may have a higher risk of developing Parkinson’s. However, there is no guarantee they will develop PD.
What if my genetic test is positive for a Parkinson’s gene?
Scientists have identified several genetic mutations that can increase the risk of developing Parkinson’s. If someone tests positive for a mutation in a Parkinson’s gene, it does not necessarily mean they will develop PD. Some people who have mutations in the genes associated with Parkinson’s never develop PD. A person may inherit a hereditary genetic mutation that increases their risk for Parkinson’s however, they may also inherit other genes, be exposed to environmental factors or have lifestyle choices that offset the risk. Genetic testing is currently available for the following genes related to Parkinson’s: GBA, PARK7, SNCA, LRRK2, parkin and PINK1.
What can I do with my genetic test results?
Recommended Reading: How Much Does Parkinson’s Medication Cost
The Interplay Between Genomic Predispositions And Environmental Factors Leads To Parkinsons
In the mid-1990s, the connection between PD and underlying genetic mutations was established,,. It is now evident that varying degrees of the interplay between genomic predispositions and aging and cellular stressors impose a risk for disease . Previous studies have shown vascular insults to the brain, repeated head trauma, neuroleptic drugs, exposure to pesticides, and manganese toxicity increase the risks of developing symptoms of PD,,. In addition, advancing age can also cause a cascade of stressors within the substantia nigra, which weakens the neurons and their ability to respond to further insults,. Ultimately, the uniqueness of the interactions between genes and the environment makes the development of a single treatment for PD difficult as they give rise to a spectrum of neuronal phenotypes that can be unique to individual patients . The development of a model with the ability to replicate the genomic and epigenetic aspects of the disease is crucial . As increasing evidence suggests that genetic mutations are key modulators of disease initiation and progression, the identification and understanding of the various genomic predispositions are required for the development of better-targeted treatments to slow the disease progression.
Fig. 1: A combinatorial spectrum of genetic risks, cellular stressors, and brain cell dysfunctions causes Parkinsons disease.
Will Findings From Pd Ipsc Models Translate To Human Clinical Trials
One of the most exciting applications of patient-derived iPSC models of PD is to validate pharmacological treatments before clinical trials. The field is still at the stage of improving human brain tissue engineering, and many different protocols are being tested and developed. However, the need for progress in clinical translation for brain disorders is extremely high, and there is no time to wait for brain tissue models to be perfect. Pioneering iPSC studies pave the road to success and identify limitations which help the community to reach a consensus on the minimal requirements to model brain disorders in vitro most accurately. It seems essential to improve the efficiency of reprogramming and differentiation protocols while trying to make those models as physiological and realistic as possible,. Some concerns are raised that in vitro neuronal development, maturation and function might be too artificial, suggesting that the model may overlook some of the critical processes that occur in vivo. Nevertheless, some defects observed in iPSC-derived neurons have already been confirmed in human postmortem brain tissues,,,,. Although this is very encouraging, it is unclear whether significant in vitro phenotypes that cannot be confirmed in postmortem brain tissue should be disregarded. Most postmortem brains also have technical limitations and may represent later stages of the disease, whereas iPSC models may represent earlier stages, preceding neurodegeneration.
Don’t Miss: Is Parkinson’s Disease Fatal
Assessment Of Family History
The majority of our identified studies use self reporting or self administered questionnaires to assess family history of PD. Categorising PD cases who have relatives with isolated tremor as having a positive family history, can significantly increase the number of familial cases, especially among early onset PD cases.
Performing individual examinations may increase the precision with which a diagnosis of PD is made in relatives of cases and controls, rather than reliance on patient reporting of diagnoses or symptoms such as tremor. It has also been shown that significant numbers of previously unrecognised PD patients can be identified by examination despite a negative family history. It can often however be difficult verifying familial diagnoses in diseases affecting the elderly as relatives are often deceased and not subjected to postmortem examination. Subclinical Parkinson’s disease, diagnosed on the basis of Lewy body pathology in people without prior symptoms of PD, is observed in up to 10% of individuals subjected to postmortem neuropathological examination. No study includes pathological examination of all relatives of both cases and controls, which currently represents the gold standard in diagnosing PD.
Scientists Locate Parkinson’s Gene
BETHESDA, Md. – For the first time, scientists have pinpointed the location of a gene they believe is responsible for some cases of Parkinson’s disease. Their discovery provides strong evidence that a genetic alteration is capable of causing the disease. The study, published in the November 15 issue of Science, sheds light on the mysterious origins of this devastating neurological disease that affects at least 500,000 Americans.
The findings are reported by National Institutes of Health scientists from the National Human Genome Research Institute and the National Institute of Neurological Disorders and Stroke , in collaboration with researchers from the UMDNJ-Robert Wood Johnson Medical School in New Brunswick, New Jersey, and the Istituto de Scienze Neurologiche in Naples, Italy.
“This exciting result gives us a powerful new tool to understand why nerve cells die in Parkinson’s disease and how to stop them from dying. It will usher in a new era of Parkinson’s disease research,” said NINDS Director Zach Hall, Ph.D.
Efforts to locate the gene intensified after an August 1995 NIH-sponsored workshop on Parkinson’s disease at which scientists from NHGRI and NINDS met Roger Duvoisin, M.D., of UMDNJ-Robert Wood Johnson Medical School. Soon after, the NIH scientists, led by Mihael Polymeropoulos, M.D., of NHGRI, began to carry out a genetic analysis of Parkinson’s disease using DNA from patients identified and followed by an international team led by Dr. Duvoisin.
Don’t Miss: 10 Early Signs Of Parkinson’s Disease That Doctors Often Miss
Genes With A Possible Role In Pd
Apart from the genes causing the six monogenic forms of PD, changes in a large number of additional genes were considered PD-causative and identified by linkage analysis or a candidate gene approach. Some of these genes even attained a PARKI designation . However, as discussed in the Genetic Classification of PD section, the link of some of these genes to PD is uncertain and not confirmed. Furthermore, mutations in some PARKs cause PD that is an inconsistent or only a minor feature of a more complex phenotype or are a very rare cause of PD . In addition, mutations in synphilin-1, NR4A2/Nurr1, POLG, mortalin, and recently presenilin-associated rhomboid-like protein were considered pathogenic based on the known function or expression/protein interaction pattern of the proteins they encode. Nevertheless, they too, are now recognized as only a minor contributor to the pool of genetic PD if at all.
Autosomal Dominant Genetic Features
People have two copies of each gene. In autosomal dominant inheritance, a child can inherit either a healthy gene or one that is not working correctly. They will have a 50% chance of inheriting a faulty gene.
Autosomal dominant genes that have associated with Parkinsons disease include:
- SNCA, or PARK1
- DJ-1
- PRKN
It is important to note that inheriting any of the genes that scientists have identified as being related to Parkinsons disease does not necessarily mean that a person will develop the condition.
Don’t Miss: Parkinson’s Disease Facial Expression
Genetic Classification Of Pd
In the current PD genetics nomenclature, 18 specific chromosomal regions, also called chromosomal locus, are termed PARK , and numbered in chronological order of their identification . In addition to being an incomplete list of known PD-related genes, this classification system, unfortunately, has a number of inconsistencies. It comprises confirmed loci, as well as those for which linkage or association could not be replicated . The causative gene has not yet been identified for all of the loci, nor do all of the identified genes contain causative or disease-determining mutations . Finally, one locus, PARK4, was designated as a novel chromosomal region associated with PD but was later found to be identical with PARK1 . It is noteworthy that some of the loci have been identified by genetic linkage analysis in large families, some based on the known function of the protein product of the gene they contain, yet others have been established by genome-wide association studies performed on a population level. A list of the PARK PD-related genes and loci is given in , along with their clinical classification, inheritance pattern , gene , status , and mode of identification.
Aao Is Associated With Multiple Genetic Components
The integrated genetic data and AAO data from the Gene4PD database provide an unprecedented opportunity to comprehensively identify the vital association between the AAO and PAGs on a large scale. Therefore, we analyzed 31 PAGs with more than five AAO items in each gene . After sorting by the median AAO of each gene, we found that 10 genes were associated with a juvenile-onset , 11 genes were associated with an early-onset , whereas another 10 genes were associated with a late-onset . Although different PAGs had specific AAO characteristics, we noted that there were large differences in the AAO for some genes, such as for PRKN, PINK1, SNCA, and LRRK2, suggesting that there are other factors that contribute to the AAO.
Figure 3. Association between Parkinsons disease-associated genes and age at onset. The association between age at onset and 31 Parkinsons disease-associated genes with more than five AAO items. The genes shown are sorted according to the median AAO or each gene. Association between AAO and 10 Parkinsons disease-associated genes with more three loss-of-function variants and deleterious missense variants.
Read Also: Parkinson’s Disease Mortality Rate